Download PDF
Diabetes aktuell 2015; 13(06): 248-254
DOI: 10.1055/s-0041-107293
Schwerpunkt
© Georg Thieme Verlag Stuttgart · New York

Moderne medikamentöse Therapie des Typ-2-Diabetes – Hin zur personalisierten Therapie

Modern medical treatment of type 2 diabetes – the way to individualized therapy
M Hanefeld
1   GWT-TUD GmbH, Studienzentrum „Prof. Hanefeld“, Dresden
2   Medizinische Klinik und Poliklinik III, Universitätsklinikum Carl-Gustav Carus, Dresden
,
S R Bornstein
2   Medizinische Klinik und Poliklinik III, Universitätsklinikum Carl-Gustav Carus, Dresden
3   Paul-Langerhans-Institut für Diabetesforschung, Technische Universität Dresden
4   Center of Regenerative Therapies, Dresden
5   Department of Diabetes and Endocrinology, Divison of Diabetes and Nutrients, King's College London, UK
,
A Barthel
2   Medizinische Klinik und Poliklinik III, Universitätsklinikum Carl-Gustav Carus, Dresden
6   Endokrinologikum Ruhr, Bochum
› Author Affiliations
Further Information

Publication History

Publication Date:
11 November 2015 (online)

Also available at
    Permissions and Reprints

Die 3 wichtigsten Neuentwicklungen der medikamentösen Therapie des Typ-2-Diabetes in den vergangenen Jahren umfassen inkretinbasierte Medikamente, SGLT2-Inhibitoren und lang wirksame Insulinanaloga. Derzeit entwickelt sich die Therapie des Typ-2-Diabetes tatsächlich zu einer personalisierten Therapie, bei der die individuelle Abwägung von Wirksamkeits- und Sicherheitsaspekten der Arzneimitteltherapie im Vordergrund steht. Die neuen Therapieoptionen bei Typ-2-Diabetes ermöglichen eine Vielzahl von Kombinationen, für die individualisierte Therapieempfehlungen von Expertengruppen und Leitlinien vorliegen. Alle Empfehlungen für Kombinationen beruhen bisher auf kontrollierten klinischen Studien. Nur für DPP-4-Inhibitoren liegen zwei Outcomestudien vor. Deshalb kommt der Risiko-Nutzen-Abwägung eine wesentliche Rolle zu, mit stärkerem Fokus auf Lebensqualität und diabetesbezogenen Komplikationen. Mit so vielen Optionen wird die Behandlung des Typ-2-Diabetes mehr denn je zu einer ars curandi.

The 3 most important new developments in the drug therapy for type 2 diabetes from the last few years encompass incretin-based drugs, SGLT2 inhibitors and long acting insulin analogues. Currently, therapy for type 2 diabetes is indeed developing in the direction of individualized regimens in which the emphasis is placed on an individual balance between efficacy and safety aspects of the drug therapy. The new therapeutic options for type 2 diabetes make numerous combinations possible, recommendations from expert groups and guidelines for individualized therapy are now available. At present, all recommendations for combinations are based on the results of controlled clinical studies. Exceptions are the DPP-4 inhibitors for which 2 outcome studies have been undertaken. Accordingly, the risk-benefit ratios are of major importance with a stronger focus on quality of life and the complications related to diabetes. With so many options in hand, the treatment of type 2 diabetes will more than ever become a curative art.

Key words

type-2-diabetes mellitus - drug therapy - guidelines - patient centered treatment
 

  • Literatur

  • 1 Gerstein HC, Miller ME. Genuth SACCORD Study Group et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011; 364: 818-828
    CrossrefGoogle Scholar
  • 2 Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Therapie des Typ-2-Diabetes – Langfassung, zuletzt geändert April 2014. http://www.versorgungsleitlinien.de/themen/diabetes2/dm2_therapie/pdf/nvl-t2d-therapie-lang-3.pdf (letzter Zugriff 29 September 2014)
    Google Scholar
  • 3 Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012; 55: 1577-1596
    CrossrefPubMedGoogle Scholar
  • 4 Kim HS, Shin JA, Lee SH et al. A comparative study of the effects of a dipeptidyl peptidase-IV inhibitor and sulfonylurea on glucose variability in patients with type 2 diabetes with inadequate glycemic control on metformin. Diabetes Technol Ther 2013; 15: 810-816
    CrossrefGoogle Scholar
  • 5 Mathieu C, Hollander P, Miranda-Palma B et al. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab 2013; 98: 1154-1162
    CrossrefGoogle Scholar
  • 6 McIntosh B, Cameron C, Singh SR et al. Choice of therapy in patients with type 2 diabetes inadequately controlled with metformin and a sulphonylurea: a systematic review and mixed-treatment comparison meta-analysis. Open Med 2012; 6: 62-74
    Google Scholar
  • 7 Meier JJ, Nauck MA. Risk of pancreatitis in patients treated with incretin-based therapies. Diabetologia 2014; 57: 1320-1324
    CrossrefGoogle Scholar
  • 8 Musso G, Gambino R, Cassader M et al. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med 2012; 44: 375-393
    CrossrefGoogle Scholar
  • 9 Nauck MA, Del Prato S, Durán-García S et al. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes Obes Metab DOI: 10.1111/dom.12327. 2014;
    Google Scholar
  • 10 Nauck MA. A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risks. Diabetes Care 2013; 36: 2126-2132
    CrossrefPubMedGoogle Scholar
  • 11 Nauck MA. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med 2011; 124: 3-18
    Google Scholar
  • 12 Pozzilli P, Leslie RD, Chan J et al. The A1C and ABCD of glycaemia management in type 2 diabetes: a physician's personalized approach. Diabetes Metab Res Rev 2010; 26: 239-244
    CrossrefGoogle Scholar
  • 13 Scirica BM, Bhatt DL, Braunwald E et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317-26
    CrossrefGoogle Scholar
  • 14 Selvin E, Steffes MW, Zhu H et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 2010; 362: 800-811
    CrossrefPubMedGoogle Scholar
  • 15 White WB, Cannon CP, Heller SR et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369: 1327-1335
    CrossrefGoogle Scholar